Latest VEGF receptors Stories
-- DIG-KT is a novel bi-specific mAb targeting VEGFR2 and Tie-2 pathways for treating cancers SHENYANG, China and DAEJEON, South Korea, Jan. 14, 2015 /PRNewswire/ -- 3SBio Inc.
-- Tanibirumab is a novel VEGFR2-neutralizing mAb for treating cancers SHENYANG, China and DAEJEON, Korea, Nov.
A major medical discovery by scientists at The University of Nottingham could lead to the development of an entirely new type of painkiller.
-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen -- INDIANAPOLIS, Sept.
A study led by researchers at Boston University School of Medicine (BUSM) demonstrates a new mechanism involving a signaling protein and its receptor that may block the formation of new blood vessels and cancer growth.
Scientific collaborators from Yale School of Medicine and University College London (UCL) have uncovered the molecular pathway by which new arteries may form after heart attacks, strokes and other acute illnesses bypassing arteries that are blocked.
Angiogenesis, the growth of new blood vessels, is a complex process during which different signalling proteins interact with each other in a highly coordinated fashion.
Persistent protein expression may explain why tumors return after therapy in glioblastoma patients.
Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects.